XML 31 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Summary of Segment Information

The table below provides segment information about the Group:

 

 

Three months ended March 31,

 

 

2025

 

 

2024

 

 

$000s

 

 

$000s

 

Revenue

 

 

142

 

 

 

15,699

 

Less:

 

 

 

 

 

 

Cost of sales

 

 

(54

)

 

 

(2,800

)

Contracted development costs (a)

 

 

(14,673

)

 

 

(6,303

)

Personnel research and development costs (b)

 

 

(5,556

)

 

 

(4,916

)

Other R&D costs (c)

 

 

(584

)

 

 

(626

)

General & administrative expenses

 

 

(7,684

)

 

 

(6,635

)

Tax expense

 

 

-

 

 

 

(244

)

Other segment items (d)

 

 

(121

)

 

 

3,513

 

Consolidated net loss

 

 

(28,530

)

 

 

(2,312

)

 

(a)
Contracted development costs primarily consist of costs incurred under agreements with contract research
organizations and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.
(b)
Personnel R&D costs primarily consist of salaries and personnel-related costs for personnel performing R&D activities or managing those activities that have been out-sourced; and consultants’ costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.
(c)
Other R&D costs include associated facility costs, equipment and other overheads that are directly attributable to R&D and depreciation of capital assets used for research and development activities.
(d)
The other segment items include foreign currency gain/(loss), net, benefit from R&D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. treasury bills.
Summary of Group's Assets and Revenues by Location

An analysis of the group’s assets and revenues by location is shown below:

 

 

U.S.A.

 

 

U.K.

 

 

Germany

 

 

Total

 

 

$000s

 

 

$000s

 

 

$000s

 

 

$000s

 

Non-current assets

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2024

 

 

-

 

 

 

4,103

 

 

 

11,166

 

 

 

15,269

 

As of March 31, 2025

 

 

-

 

 

 

4,068

 

 

 

11,440

 

 

 

15,508

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue analysis for the three months ended December 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Research collaboration

 

 

-

 

 

 

15,556

 

 

 

-

 

 

 

15,556

 

Royalties

 

 

-

 

 

 

-

 

 

 

143

 

 

 

143

 

 

 

-

 

 

 

15,556

 

 

 

143

 

 

 

15,699

 

 

 

 

 

 

 

 

 

 

 

 

`

 

Revenue analysis for the three months ended March 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Research collaboration

 

 

-

 

 

 

142

 

 

 

-

 

 

 

142

 

Royalties

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

142

 

 

 

-

 

 

 

142